Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

British Journal of Haematology

Volumn 145, Issue 6, 2009, Pages 681-708

  Lonial, Sagar ^a   Cavenagh, Jamie ^b  

^a EMORY UNIVERSITY   (United States)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Bortezomib; Combination therapy; Lenalidomide; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ANEMIA; ANXIETY DISORDER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GERIATRIC CARE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFECTION; INSOMNIA; INTESTINE OBSTRUCTION; LEUKOPENIA; LIVER DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MENTAL DISEASE; METABOLIC DISORDER; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MYOPATHY; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOMNOLENCE; STEM CELL TRANSPLANTATION; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VASCULITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 66849111894     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07649.x     Document Type: Review

References (181)

1. Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T.B., Lakhal, A., Romdhane, N.B., Omri, H.E., Elloumi, M., Belaaj, H., Jeddi, R., Aissaoui, L., Ksouri, H., Hassen, A.B., Msadek, F., Saad, A., Hsairi, M., Boukef, K., Amouri, A., Louzir, H., Dellagi, K. Abdeladhim, A.B. (2008) Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood, 111, 1805 1810.
2. Ailawadhi, S., Miller, K.C., DePaolo, D., Whitworth, A., Yu, J., Padmanabhan, S., Czuczman, M., Bernstein, Z., Lee, K. Chanan-Khan, A. (2008) Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide for the treatment of previously untreated multiple myeloma. Haematologica, 93, 83.
3. Alexanian, R., Barlogie, B. Tucker, S. (1990) VAD-based regimens as primary treatment for multiple myeloma. American Journal of Hematology, 33, 86 89. (Pubitemid 20040083)
4. Alexanian, R., Dimopoulos, M.A., Delasalle, K. Barlogie, B. (1992) Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887 890.
5. Anderson, K.C., Kyle, R.A., Rajkumar, S.V., Stewart, A.K., Weber, D. Richardson, P. (2008) Clinically relevant end points and new drug approvals for myeloma. Leukemia, 22, 231 239.
6. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe francais du myelome. New England Journal of Medicine, 335, 91 97. (Pubitemid 26240110)
7. Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Yakoub, A.I., Bourhis, J.H., Garderet, L., Pegourie, B., Dumontet, C., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Caillot, D., Grobois, B., vet-Loiseau, H., Moreau, P. Facon, T. (2006) Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood, 108, 3289 3294. (Pubitemid 44776865)
8. Augustson, B.M., Begum, G., Dunn, J.A., Barth, N.J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J.A. Drayson, M.T. (2005) Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 23, 9219 9226. (Pubitemid 46260177)
9. Badros, A., Goloubeva, O., Fenton, R., Rapoport, A.P., Akpek, G., Harris, C., Ruehle, K., Westphal, S. Meisenberg, B. (2006a) Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clinical Lymphoma and Myeloma, 7, 210 216. (Pubitemid 44823806)
10. Badros, A., Dalal, J.S., Goloubeva, O., Thompson, J., Yager, K., Ilyas, C., Rapoport, A.P., Fenton, R.G., Akpek, G., Yanovich, S. Sausville, E. (2006b) Neurotoxicity of bortezomib therapy in multiple myeloma (MM): a single center experience. Blood, 108, 1008a.
11. Bahlis, N., Song, K., Trieu, Y., Roland, B., Masih-Khan, E., Chang, H., Bruyere, H., Mansoor, A., Horsman, D., Eliasziw, M., Stewart, D. Reece, D. 2007) Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but not del17p13 in multiple myeloma: results of the Canadian MM016 Trial. Blood, 110, Abstract 3597.
12. Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. Crowley, J. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 1021 1030. (Pubitemid 43357806)
13. Barlogie, B., Anaissie, E., Shaughnessy, Jr., J.D., van Rhee, F., Hollmig, K., Pineda-Roman, M., Mohiuddin, A., Zangari, M., Tricot, G. Crowley, J. (2007a) Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma (MM). Journal of Clinical Oncology, 25, 446s.
14. Barlogie, B., Anaissie, E., van, R.F., Haessler, J., Hollmig, K., Pineda-Roman, M., Cottler-Fox, M., Mohiuddin, A., Alsayed, Y., Tricot, G., Bolejack, V., Zangari, M., Epstein, J., Petty, N., Steward, D., Jenkins, B., Gurley, J., Sullivan, E., Crowley, J. Shaughnessy, Jr., J.D. (2007b) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology, 138, 176 185. (Pubitemid 46978271)
15. Barlogie, B., Pineda-Roman, M., van, R.F., Haessler, J., Anaissie, E., Hollmig, K., Alsayed, Y., Waheed, S., Petty, N., Epstein, J., Shaughnessy, Jr., J.D., Tricot, G., Zangari, M., Zeldis, J., Barer, S. Crowley, J. (2008a) Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood, 112, 3115 3121.
16. Barlogie, B., Anaissie, E., van Rhee, F., Shaughnessy, J., Haessler, J., Pineda-Roman, M., Hollmig, K., Epstein, J. Crowley, J. (2008b) Total Therapy for myeloma: 10% cure rate with TT1 suggested by >10 year continuous complete remission; bortezomib in TT3 overcomes poor-risk associated with T(4;14) and Del TP53 in TT2. Journal of Clinical Oncology, 26 May 20 suppl: abstract 8516).
17. Bartlett, J.B., Dredge, K. Dalgleish, A.G. (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Review. Cancer, 4, 314 322. (Pubitemid 38525287)
18. TM], pegylated liposomal doxorubicin [DOXIL/CAELYX®] and dexamethasone in the treatment of previously untreated multiple myeloma patients: impact on quality-of-life. Blood, 110, 1058a.
19. Belch, A., Reece, D., Bahlis, N., White, D. Plante, R.K. (2007b) Efficacy and safety of liposomal doxorubicin (DOXIL/CAELYX), bortezomib (VELCADE) and dexamethasone in the treatment of previously untreated multiple myeloma patiens: impact of cytogenetic profile. Haematologica, 92, 180.
20. Berenson, J.R., Yellin, O., Woytowitz, D., Flam, M.S., Cartmell, A., Patel, R., Duvivier, H., Nassir, Y. Swift, R.A. (2007) Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients (pts) with newly diagnosed multiple myeloma (MM): an effective and well-tolerated frontline regimen. Blood, 110, 1054a.
21. Bergsagel, P.L. (2008) A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy. Leukemia, 22, 673 675.
22. Bladé, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European group for blood and marrow transplant. British Journal of Haematology, 102, 1115 1123.
23. Bladé, J., San Miguel, J.F., Fontanillas, M., Esteve, J., Maldonado, J., Alcala, A., Brunet, S., Garcia-Conde, J., Besalduch, J., Moro, M.J., Fernandez-Calvo, J., Conde, E., Font, L., Gardella, S., Carnero, M., Carbonell, F., Marti, J.M., Hernandez-Martin, J., Ortega, F., Besses, C., Ribera, J.M., Trujillo, J., Escudero, M.L., Rozman, C., Estape, J. Montserrat, E. (2001) Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematology Journal, 2, 272 278. (Pubitemid 32771602)
24. Borrello, I., Ferguson, A., Huff, C.A., George, S., Biedryzcki, B., Cornblath, D. Chaudhry, V. (2006) Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma: efficacy and neurotoxicity. Blood, 108, 1006a.
25. Breitkreutz, I., Raab, M., Vallet, S., Hideshima, T., Raje, N., Mitsiades, C. Chauhan, D. (2007) Lenalidomide and bortezomib: targeting osteoclastogenesis, osteoclast survival factors, and bone remodeling markers in multiple myeloma. Blood, 110, 359a.
26. Breitkreutz, I., Raab, M.S., Vallet, S., Hideshima, T., Raje, N., Mitsiades, C., Chauhan, D., Okawa, Y., Munshi, N.C., Richardson, P.G. Anderson, K.C. (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia, 22, 1925 1932.
27. Caravita, T., Siniscalchi, A., Spagnoli, A., Petrucci, M.T., Vincenzo, F. Falco, P. (2008) Role of thalidomide on velcade neuropathy in myeloma patients. Haematologica, 93, 258.
28. Cavo, M., Benni, M., Ronconi, S., Fiacchini, M., Gozzetti, A., Zamagni, E., Cellini, C., Tosi, P., Baccarani, M. Tura, S. (2002) Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica, 87, 934 942.
29. Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., de Vivo, A., Testoni, N., Nicci, C., Terragna, C., Grafone, T., Perrone, G., Ceccolini, M., Tura, S. Baccarani, M. (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood, 106, 35 39. (Pubitemid 40967171)
30. Cavo, M., Testoni, N., Terragna, C., Zamagni, E., Tacchetti, P., Nicci, C., Renzulli, M., Montanari, E., Perrone, G., Cangini, D., Grafone, T., Ceccolini, M., Brioli, A.-M., Martinelli, G., Tosi, P. Baccarani, M. (2006) Up-front thalidomide-dexamethasone (THAL) and double autologous transplantation (double TX) for multiple myeloma: comparison with double TX without added thalidomide and prognostic implications of chromosome 13 deletion and translocation t(4;14). Blood, 108, 878a.
31. Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di, R.F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de, V.A., Gozzetti, A., Lazzaro, A., Tura, S. Baccarani, M. (2007a) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. Journal of Clinical Oncology, 25, 2434 2441. (Pubitemid 46999214)
32. Cavo, M., Patriarca, F., Tacchetti, P., Galli, M., Perrone, G., Petrucci, M.T., Briolli, A., Bringhen, S., Pantani, L., Tosi, P., Crippa, C., Zamagni, E., Di Raimondo, F., Narni, F., Cellini, C., Ceccolini, M., Pescosta, N., Goldaniga, M.C., Montefusco, V., Callea, V., De Stefano, V., Caravita, T., Boccadoro, M. Baccarani, M. (2007b) Bortezomib (Velcade®)-thalidomide- dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood, 110, 30a.
33. Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M., Pantani, L., Ceccolini, M., Galli, M., Di Raimondo, F., Crippa, C. Zamagni, E. 2008) Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide- dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood, 112, Abstract 158.
34. Chanan-Khan, A.A., Kaufman, J.L., Mehta, J., Richardson, P.G., Miller, K.C., Lonial, S., Munshi, N.C., Schlossman, R., Tariman, J. Singhal, S. (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood, 109, 2604 2606. (Pubitemid 46425908)
35. Chen, S., Jiang, B., Qiu, L., Yu, L., Zhong, Y. Gao, W. (2007a) Bortezomib plus thalidomide treatment of newly diagnosed patients with multiple myeloma - efficacy and neurotoxicity: results of a multicenter study. Blood, 110, 1053a.
36. Chen, N., Lau, H., Kong, L., Kumar, G., Zeldis, J.B., Knight, R. Laskin, O.L. (2007b) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. Journal of Clinical Pharmacology, 47, 1466 1475. (Pubitemid 350115306)
37. Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 1875 1883. (Pubitemid 36532313)
38. Chim, C.S., Liang, R., Lie, A.K.W. Kwong, Y.L. (2007) Induction with sequential bortezomib/thalidomide/dexamethasone after VAD results in significant cytoreduction prior to BMT in multiple myeloma (MM). Haematologica, 92, 181.
39. Corso, A., Barbarano, L., Mangiacavalli, S., Montalbetti, L., Brasca, P., Zappasodi, P., Carella, A., Spriano, M., Alessandrino, E.P., Cairoli, R., Petro, D., Varettoni, M., Bernasconi, P., Lazzarino, M. Morra, E. (2007) Bortezomib with high-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy. Blood, 110, 1051a.
40. Dimopoulos, M.A., Pouli, A., Zervas, K., Grigoraki, V., Symeonidis, A., Repoussis, P., Mitsouli, C., Papanastasiou, C., Margaritis, D., Tokmaktsis, A., Katodritou, I., Kokkini, G., Terpos, E., Vyniou, N., Tzilianos, M., Chatzivassili, A., Kyrtsonis, M.C., Panayiotidis, P. Maniatis, A. (2003) Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Annals of Oncology, 14, 1039 1044. (Pubitemid 36950167)
41. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San, M.J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123 2132. (Pubitemid 350146107)
42. Drach, J., Odelga, V., Ackermann, J., Sagaster, V., Kauffman, H., Worel, N., Rabitsch, W., Kaihs, P. Zielinski, C. (2008) VTD represents an active induction regimen for patients with multiple myeloma. Haematologica, 93, 87.
43. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467 1473. (Pubitemid 44264086)
44. Eom, H.S., Kim, Y.K., Chung, J.S., Kim, K.H., Kim, H.J. Jin, J.Y. (2008) VTD induction chemotherapy followed by MPT maintenance as a first line treatment for patients with multiple myeloma who are non-transplant candidates. Haematologica, 93, 88.
45. Eriksson, T., Hoglund, P., Turesson, I., Waage, A., Don, B.R., Vu, J., Scheffler, M. Kaysen, G.A. (2003) Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. Journal of Pharmacy and Pharmacology, 55, 1701 1706. (Pubitemid 38054404)
46. Facon, T., Mary, J.Y., Pegourie, B., Attal, M., Renaud, M., Sadoun, A., Voillat, L., Dorvaux, V., Hulin, C., Lepeu, G., Harousseau, J.L., Eschard, J.P., Ferrant, A., Blanc, M., Maloisel, F., Orfeuvre, H., Rossi, J.F., Azais, I., Monconduit, M., Collet, P., Anglaret, B., Yakoub-Agha, I., Wetterwald, M., Eghbali, H., Vekemans, M.C., Maisonneuve, H., Troncy, J., Grosbois, B., Doyen, C., Thyss, A., Jaubert, J., Casassus, P., Thielemans, B. Bataille, R. (2006) Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood, 107, 1292 1298. (Pubitemid 43242361)
47. Facon, T., Mary, J.Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J.L., Guillerm, G., Chaleteix, C., Dib, M., Voillat, L., Maisonneuve, H., Troncy, J., Dorvaux, V., Monconduit, M., Martin, C., Casassus, P., Jaubert, J., Jardel, H., Doyen, C., Kolb, B., Anglaret, B., Grosbois, B., Yakoub-Agha, I., Mathiot, C. vet-Loiseau, H. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet, 370, 1209 1218. (Pubitemid 47516593)
48. Foa, R., Weber, D., Dimopoulos, M., Olesnyckyj, M., Zhinuan, Y., Zeldis, J. Chanan-Khan, A.A. 2007) Lenalidomide/Dexamethasone improves response and prolongs time to progression, even in patients with IgA multiple myeloma: a sub-analysis of the MM-009/010 studies. Blood, 110, Abstract 4839.
49. Garrett, I.R., Chen, D., Gutierrez, G., Zhao, M., Escobedo, A., Rossini, G., Harris, S.E., Gallwitz, W., Kim, K.B., Hu, S., Crews, C.M. Mundy, G.R. (2003) Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. Journal of Clinical Investigation, 111, 1771 1782. (Pubitemid 38057757)
50. Gentile, M., Ciolli, S., Petrucci, M.T., Galimberti, S., Mele, G. Casulli, A.F. (2008) Bortezomib (Vel) based regimens in multiple myeloma (MM) patients with renal impairment (RI): a preliminary retrospective Italian multicenter study. Haematologica, 93, 84.
51. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Hayman, S.R. Kumar, S.K. (2006) High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Review of Anticancer Therapy, 6, 343 360. (Pubitemid 44192917)
52. Gladney, S.P., Lonial, S. Kaufman, J.L. (2008) Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. Clinical Lymphoma and Myeloma, 8, 52 54.
53. Goldschmidt, H., Sonneveld, P., Breitkreutz, I., van der Holt, B., Benner, A., Barge, R.M.Y., Salwender, H., Bos, G.M.J., Glasmacher, A., Raymakers, R., Scheid, C., Huijgens, P.C., Naumann, R., van Oers, M.H., Hanel, A., Vellenga, E., Martin, H., Wijermans, P.W., Ho, A.D., Westveer, P.H.M., Verhoef, G.E., Mazitschek, U. Lokhorst, H.M. (2005) HOVON 50/GMMG-HD3-Trial: Phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. Blood, 106, 128a.
54. Harousseau, J.-L., Jagannath, S., Richardson, P.G., Sonneveld, P., Schuster, M.W., Esseltine, D.-L. Anderson, K.C. (2006a) Bortezomib in combination with high-dose dexamethasone (HD dex) and erythropoietin (EPO) does not result in an increased risk of thromboembolic complications. Blood, 108, 1011a.
55. Harousseau, J.-L., Attal, M., Leleu, X., Troncy, J., Pegourie, B., Stoppa, A.-M., Hulin, C., Benboubker, L., Fuzibet, J.-G., Renaud, M., Moreau, P. Avet-Loiseau, H. (2006b) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica, 91, 1498 1505. (Pubitemid 44736116)
56. Harousseau, J.L., Mathiot, C., Attal, M., Marit, G., Caillot, D., Mohty, M., Hulin, C., Facon, T., Webb, I. Moreau, P. (2007) VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. Blood, 110, 139a.
57. Harousseau, J.L., Mathiot, C., Attal, M., Marit, G., Caillot, D., Hulin, C., Facon, T., Webb, I., Avet-Loiseau, H. Moreau, P. (2008) Bortezomib/ dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial. Journal of Clinical Oncology, 26, 455s.
58. Hernandez, J.M., Garcia-Sanz, R., Golvano, E., Blade, J., Fernandez-Calvo, J., Trujillo, J., Soler, J.A., Gardella, S., Carbonell, F., Mateo, G. San Miguel, J.F. (2004) Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. British Journal of Haematology, 127, 159 164. (Pubitemid 39371808)
59. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071 3076. (Pubitemid 32691956)
60. Hulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Voillat, L., Mathiot, C., Casassus, P., Decaux, O., Flesch, M., Garderet, L. Moreau, P. (2007) Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood, 110, 31a.
61. Hussein, M.A. (2006) Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thrombosis and Haemostasis, 95, 924 930. (Pubitemid 43933748)
62. Hussein, M.A., Baz, R., Srkalovic, G., Agrawal, N., Suppiah, R., Hsi, E., Andresen, S., Karam, M.A., Reed, J., Faiman, B., Kelly, M. Walker, E. (2006) Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clinic Proceedings, 81, 889 895. (Pubitemid 43993480)
63. Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P.G., Niesvizky, R., Alexanian, R., Limentani, S.A., Alsina, M., Adams, J., Kauffman, M., Esseltine, D.L., Schenkein, D.P. Anderson, K.C. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal Haematology, 127, 165 172. (Pubitemid 39371809)
64. Jagannath, S., Barlogie, B., Berenson, J.R., Singhal, S., Alexanian, R., Srkalovic, G., Orlowski, R.Z., Richardson, P.G., Anderson, J., Nix, D., Esseltine, D.L. Anderson, K.C. (2005) Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer, 103, 1195 1200. (Pubitemid 40328090)
65. Jagannath, S., Durie, B.G.M., Wolf, J.L., Camacho, E.S., Irwin, D., Lutzky, J., McKinley, M., Gabayan, A.E., Mazumder, A., Crowley, J. Vescio, R. (2006) Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Blood, 108, 238a 239a.
66. Jagannath, S., Bensinger, B., Vescio, R., Camacho, E., Wolf, J., Irwin, D., Capo, G., McKinley, M., Vesole, D.H., Mazumder, A., Crowley, J., Esseltine, D. Durie, B. (2007) A phase II study of bortezomib (Velcade®), cylophosphamide (Cytoxan®), thalidomide (Thalomid®) and dexamethasone as first-line therapy for multiple myeloma. Blood, 110, 63a.
67. Jakubowiak, A.J., Al-Zoubi, A., Kendall, T., Brozo, C., Khaled, Y., Mineishi, S., Hari, M., Ahmed, A., Friedman, J., Kaminski, M.S., Soengas, M.S. Talpaz, M. (2007) Combination therapy with bortezomib (VELCADE), Doxil, and dexamethasone (VDD) in newly diagnosed myeloma: updated results of phase II clinical trial. Haematologica, 92, 180 181.
68. Kastritis, E., Anagnostopoulos, A., Roussou, M., Gika, D., Matsouka, C., Barmparousi, D., Grapsa, I., Psimenou, E., Bamias, A. Dimopoulos, M.A. (2007) Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica, 92, 546 549. (Pubitemid 350144300)
69. Kaufman, J.L., Gleason, C., Heffner, L. Lonial, S. (2007) Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. Blood, 110, 1055a.
70. Knudsen, L.M., Hjorth, M. Hippe, E. (2000) Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Europen Journal of Haematology, 65, 175 181.
71. Koh, K.R., Janz, M., Mapara, M.Y., Lemke, B., Stirling, D., Dorken, B., Zenke, M. Lentzsch, S. (2005) Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood, 105, 3833 3840. (Pubitemid 40656125)
72. Kropff, M., Liebisch, P., Wand, H., Weisel, K., Gann, C.-N., Knop, S. Einsele, H. 2007) Dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed multiple myeloma. Blood, 110, Abstract 3599.
73. Kumar, S., Hayman, S.R., Buadi, F.K., Lacy, M.Q., Stewart, K., Greipp, P.R., Russell, S., Zeldenrust, S., Gertz, M.A., Bergsagel, L., Fonseca, R., Allred, J., Campbell, M., Lust, J.A., Witzig, T.E., Kyle, R.A., Rajkumar, S.V. Dispenzieri, A. 2007a) Phase II trial of lenalidomide, cyclophosphamide, and dexamethasone (CRd) for newly diagnosed myeloma. Blood, 110, Abstract 190.
74. Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Gastineau, D.A., Litzow, M.R., Fonseca, R., Roy, V., Rajkumar, S.V. Gertz, M.A. (2007b) Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia, 21, 2035 2042. (Pubitemid 47299979)
75. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516 2520.
76. Kyle, R.A. Rajkumar, S.V. (2004) Multiple myeloma. New England Journal of Medicine, 351, 1860 1873.
77. Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.E., Therneau, T.M. Greipp, P.R. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78, 21 33. (Pubitemid 36033957)
78. Kyle, R.A., Leong, T., Li, S., Oken, M.M., Kay, N.E., Van Ness, B. Greipp, P.R. (2006) Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer, 106, 1958 1966. (Pubitemid 43673211)
79. Lacy, M.Q., Gertz, M.A., Dispenzieri, A., Hayman, S.R., Geyer, S., Kabat, B., Zeldenrust, S.R., Kumar, S., Greipp, P.R., Fonseca, R., Lust, J.A., Russell, S.J., Kyle, R.A., Witzig, T.E., Bergsagel, P.L., Stewart, A.K. Rajkumar, S.V. (2007) Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clinic Proceedings, 82, 1179 1184. (Pubitemid 47502875)
80. Ladetto, M., Pagliano, G., Avonto, I., Santo, L., Ferrero, S., Cavallo, F., Astolfi, M., Pregno, P., Crippa, C., Liberati, A.M., Callea, V., De Rosa, L., Falcone, A., Grasso, M., Drandi, D., Boccadoro, M. Palumbo, A. (2007) Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients. Blood, 110, Abstract 530.
81. Lahuerta, J.J., Mateos, M.V., Martinez-Lopez, J., Rosinol, L., Sureda, A., De la, R.J., Garcia-Larana, J., Martinez-Martinez, R., Hernandez-Garcia, M.T., Carrera, D., Besalduch, J., De, A.F., Ribera, J.M., Escoda, L., Hernandez-Ruiz, B., Garcia-Frade, J., Rivas-Gonzalez, C., Alegre, A., Blade, J. San Miguel, J.F. (2008) Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. Journal of Clinical Oncology, 26, 5775 5782.
82. Lokhorst, H., Schmidt-Wolf, I., Sonneveld, P., van der Holt, B., Martin, H., Barge, R.M.Y., Bertsch, U., Schlenzka, J., Bos, G.M.J. Croockewit, S. (2008a) Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica, 93, 124 127.
83. Lokhorst, H., van der Holt, B., Zweegman, S., Von Dem Borne, P., Bos, G., Croockewit, S., Cornelissen, J.J., van Oers, M., Schaafsma, M.R., Sinnige, H., Delforge, M., de Weerdt, O., Wijermans, P.W., Wittebol, S., Vellenga, E., Jie, A., Berenschot, H., Marinus Marwijk-kooy, M. Sonneveld, P. (2008b) Final analysis of HOVON-50 randomized phase III study on the effect of thalidomide combined with adriamycine, dexamethasone (AD) and high dose melphalan (HDM) in patients with multiple myeloma (MM). Blood, 112, Abstract 157.
84. Lonial, S. Gertz, M.A. (2008) Eliminating the complete response penalty from myeloma response assessment. Blood, 111, 3297 3298.
85. Lonial, S., Waller, E.K., Richardson, P.G., Jagannath, S., Oriowski, R.Z., Giver, C.R., Jaye, D.L., Barlogie, B., Heffner, L.T. Anderson, K.C. (2005) Bortezomib-associated transient and cyclical thrombocytopenia: evidence for lack of marrow cytotoxicity. Journal of Clinical Oncology, 23, 587s.
86. Lonial, S., Kaufman, J., Langston, A.A., Heffner, L.T., Torre, C., Lechowicz, M.J., Flowers, C., McMillan, S., Arnold, M. Waller, N.K. (2007) A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration. Blood, 110, Abstract 949.
87. Lonial, S., Richardson, P.G., San-Miguel, J., Sonneveld, P., Schuster, M., Blade, J., Cavenagh, J., Rajkumar, S.V., Jakubowiak, A.J., Esseltine, D., Anderson, K.C. Harousseau, J.-L. (2008) Characterisation of haematologic profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. British Journal of Haematology, 143, 222 229.
88. Ludwig, H., Hajek, R., Tothova, E., Drach, J., Adam, Z., Labar, B., Egyed, M., Spicka, I., Gisslinger, H., Greil, R., Kuhn, I., Zojer, N. Hinke, A. (2008a) Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood, doi :.
89. Ludwig, H., Adam, Z., Greil, R., Keil, F., Zojer, N., Thaler, J., Gisslinger, H. Lang, A. (2008b) Recovery of renal impairment by bortezomib-doxorubicin-dexamethasone (BDD) in multiple myeloma (MM) patients with acute renal failure. Results from an ongoing phase II study. Haematologica, 93, 177.
90. Macro, M., Divine, M., Uzunhan, Y., Jaccard, A., Bouscary, D., Leblond, V., Janvier, M., Genet, P., Castaigne, S., Royer, B., Allard, C., Chevret, S. Fermand, J.P. (2006) Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. Blood, 108, 22a.
91. Mateos, M.V., Hernandez, J.M., Hernandez, M.T., Gutierrez, N.C., Palomera, L., Fuertes, M., Diaz-Mediavilla, J., Lahuerta, J.J., De la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., De Arriba, F., Alegre, A., Oriol, A., Carrera, D., Garcia-Larana, J., Garcia-Sanz, R., Blade, J., Prosper, F., Mateo, G., Esseltine, D.L., van de Velde, H. San Miguel, J.F. (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood, 108, 2165 2172. (Pubitemid 44497496)
92. Mateos, M.V., Hernandez, J.M., Hernandez, M.T., Gutierrez, N.C., Palomera, L., Fuertes, M., Garcia, P., Lahuerta, J.J., De la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., De Arriba, F., Alegre, A., Oriol, A., Carrera, D., Garcia-Larana, J., Garcia-Sanz, R., Bladé, J., Prosper, F., Mateo, G., Esseltine, D.L., van de Velde, H. San Miguel, J.F. (2007) Frontline VMP in elderly MM patients: extended follow-up. Haematologica, 92, 180.
93. Mateos, M.-V., Oriol, A., Martinez, J., Cibeira, M., de Paz, R., Terol, M.-J., García-Laraña, J., Bengoechea, E., Martínez, R., Martin, A., De Arriba, F., Palomera, L., Hernández, J., Bello, J.L., Martín, M.-L., González, Y., Blade, J., Lahuerta, J.J. San Miguel, J.F. 2008a) Bortezomib (Velcade)-Melphalan-Prednisone (VMP) versus Velcade-Thalidomide-Prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for velcade: an alkylating or an immunomodulator agent? Blood, 112, Abstract 651.
94. Mateos, M.V., Hernandez, J.M., Hernandez, M.T., Gutierrez, N.C., Palomera, L., Fuertes, M., Garcia-Sanchez, P., Lahuerta, J.J., De la, R.J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., Alegre, A., De, A.F., Oriol, A., Carrera, D., Garcia-Larana, J., Garcia-Sanz, R., Blade, J., Prosper, F., Mateo, G., Esseltine, D.L., van, d.V. San Miguel, J.F. (2008b) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica, 93, 560 565.
95. Mazumder, A., Jagannath, S. Vesole, D. (2007) The effect of induction
96. Mazumder, A., Kaufman, J., Niesvizky, R., Lonial, S., Vesole, D. Jagannath, S. (2008) Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia, 22, 1280 1281.
97. Mihelic, R., Kaufman, J.L. Lonial, S. (2007) Maintenance therapy in multiple myeloma. Leukemia, 21, 1150 1157. (Pubitemid 46831803)
98. Mileshkin, L., Stark, R., Day, B., Seymour, J.F., Zeldis, J.B. Prince, H.M. (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. Journal of Clinical Oncology, 24, 4507 4514. (Pubitemid 46630990)
99. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N.C., Treon, S.P. Anderson, K.C. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99, 4525 4530. (Pubitemid 34627223)
100. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C., Hideshima, T. Anderson, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 2377 2380. (Pubitemid 36302084)
101. Morgan, G.J., Davies, F.E., Owen, R.G., Rawstron, A.C., Bell, S., Cocks, K., Gregory, W., Jackson, G., Drayson, M.T., Jenner, M.W. Child, J.A. (2007) Thalidomide combinations improve response rates; results from the MRC IX study. Blood, 110, 1051a.
102. Mukherjee, S., Raje, N., Schoonmaker, J.A., Liu, J.C., Hideshima, T., Wein, M.N., Jones, D.C., Vallet, S., Bouxsein, M.L., Pozzi, S., Chhetri, S., Seo, Y.D., Aronson, J.P., Patel, C., Fulciniti, M., Purton, L.E., Glimcher, L.H., Lian, J.B., Stein, G., Anderson, K.C. Scadden, D.T. (2008) Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. Journal of Clinical Investigation, 118, 491 504.
103. Mulkerin, D., Remick, S., Takimoto, C., Ivy, P., Karol, M. Eton, O 2007) Safety, tolerability, and pharmacology of bortezomib in cancer patients with renal failure requiring dialysis: results from a prospective phase 1 study. Blood, 110, Abstract 3477.
104. Myeloma Trialists' Collaborative Group 1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Journal of Clinical Oncology, 16, 3832 3842.
105. National Comprehensive Cancer Network (NCCN) 2009) NCCN Clinical Practice Guidelines in Oncology™ Multiple Myeloma (V2.2009). National Comprehensive Cancer Network Inc., Fort Washington, PA, http://www.nccn.org/ professionals/physician-gls/PDF/myeloma.pdf.
106. Niesvizky, R., Spencer, A., Wang, M., Weber, D., Chen, C., Dimopoulos, M.A., Yu, Z., Delap, R., Zeldis, J. Knight, R.D. (2006) Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin. Journal of Clinical Oncology, 24, 423s.
107. Niesvizky, R., Stern, J., DiCarlo, B., Jayabalan, D., Zafar, F., Pearse, R., Lent, R., Ely, S., Mark, T., Shore, T., Harpel, J., Schuster, M., Leonard, J., Myers, T., Chen-Kiang, S. Coleman, M. (2007) Bortezomib/Dex/Doxil: Breaks Plateau in MM. Haematologica, 92, 161.
108. Niesvizky, R., Stern, J., Mark, T., Schuster, J., Shore, T.B., Harpel, J.G., Pearse, R.N., Zafar, F., Manco, M. Coleman, M. (2008a) Bortezomib, cyclophosphamide, and filgrastin leads to high-yield CD34+ stem cell collections in multiple myeloma. Journal of Clinical Oncology, 26 May 20 suppl: abstract 8587).
109. Niesvizky, R., Jayabalan, D.S., Christos, P.J., Furst, J.R., Naib, T., Ely, S., Jalbrzikowski, J., Pearse, R.N., Zafar, F., Pekle, K., Larow, A., Lent, R., Mark, T., Cho, H.J., Shore, T., Tepler, J., Harpel, J., Schuster, M.W., Mathew, S., Leonard, J.P., Mazumdar, M., Chen-Kiang, S. Coleman, M. (2008b) BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood, 111, 1101 1109.
110. Oakervee, H.E., Popat, R., Curry, N., Smith, P., Morris, C., Drake, M., Agrawal, S., Stec, J., Schenkein, D., Esseltine, D.L. Cavenagh, J.D. (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology, 129, 755 762. (Pubitemid 40904525)
111. Oakervee, H., Popat, R. Cavenagh, J.D. (2007) Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment. Leukaemia & Lymphoma, 48, 1910 1921. (Pubitemid 47542977)
112. Odelga, V., Ackermann, J., Sagaster, V., Kaufmann, H., Zielinski, C. Drach, J. (2007) Rapid remission induction by VTD (VELCADE, THALIDOMIDE, DEXAMETHASON) in patients with multiple myeloma and high tumor burden at diagnosis. Haematologica, 92, 182.
113. Offidani, M., Corvatta, L., Polloni, C., Piersantelli, M.-N., Gentili, S., Galieni, P., Catarini, M., Mele, A., Brunori, M., Samori, A., Visani, G., Blasi, N., Ferranti, M., Alesiani, F., Burattini, M., Centurioni, R. Leoni, P. (2008) Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) is feasible and effective in an unselected multiple myeloma population aged 75 or more years. Haematologica, 93, 88.
114. Orlowski, R.Z., Peterson, B.L., Sanford, B., Chanan-Khan, A.A., Zehngebot, L.M., Watson, P.R., Caligiuri, M.A. Larson, R.A. (2006) Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B Study 10301. Blood, 108, 239a.
115. Ozaki, S., Tanaka, O., Fujii, S., Shigekiyo, Y., Miki, H., Choraku, M., Kagawa, K., Asano, J., Takeuchi, K., Kitazoe, K.I., Hashimoto, T., Abe, M. Matsumoto, T. (2007) Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. International Journal of Hematology, 86, 180 185. (Pubitemid 47425199)
116. Paiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J.J., Montalbán, M.A., Sureda, A., Montejano, L., Gutierrez, N.C., de Coca, A.G., de las Heras, N., Mateos, M.V., Lopez-Berges, M.C., Garcia-Boyero, R., Galende, J., Hernandez, J., Palomera, L., Carrera, D., Martinez, R., de la Rubia, J., Martin, A., Blade, J., Lahuerta, J.J., Alberto Orfao, A. San Miguel, J.F. (2008) Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, 112, 4017 4023.
117. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., Catalano, L., Zamagni, E., Petrucci, M.T., De Stefano, V., Ceccarelli, M., Ambrosini, M.T., Avonto, I., Falco, P., Ciccone, G., Liberati, A.M., Musto, P. Boccadoro, M. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 367, 825 831. (Pubitemid 43363369)
118. 2 in elderly newly diagnosed patients: An interim analysis. Blood, 110, 138a.
119. Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omede, P., Ambrosini, M.T., Gay, F., Bringhen, S., Musto, P., Foa, R., Knight, R., Zeldis, J.B., Boccadoro, M. Petrucci, M.T. (2007b) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. Journal of Clinical Oncology, 25, 4459 4465. (Pubitemid 350063804)
120. Palumbo, A., Falco, P., Corradini, P., Crippa, C., Di Raimondo, F., Falcone, A., Giuliani, N., Musto, P., Pregno, P., Aitoro, G., Luraschi, A. Nozza, A. (2008a) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: kinetics of neutropenia, thrombocytopenia, and time-to-event results. Haematologica, 93, 85.
121. Palumbo, A., Bringhen, S., Liberati, A.M., Caravita, T., Falcone, A., Callea, V., Montanaro, M., Ria, R., Capaldi, A., Zambello, R., Benevolo, G., Derudas, D., Dore, F., Cavallo, F., Gay, F., Falco, P., Ciccone, G., Musto, P., Cavo, M. Boccadoro, M. (2008b) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood, 112, 3107 3114.
122. Palumbo, A., Schlag, R., Khuageva, N., Shpilberg, O., Dimopoulos, M. Kropff, M. (2008c) Prolonged therapy with bortezomib plus melphalan-prednisone (VMP) results in improved quality and duration of response in the phase III VISTA study in previously untreated multiple myeloma (MM). Haematologica, 93, 83.
123. Palumbo, A., Falco, P., Corradini, P., Crippa, C., Patriarca, F. Rossini, F. (2008d) PAD, ASCT (MEL100) and LP in elderly newly diagnosed myeloma. Journal of Clinical Oncology, 26 May 20 suppl: abstract 0438).
124. Palumbo, A., Cavallo, F., Pagliano, G., Ferrero, S., Santo, L. Magarotto, V. (2008e) Early consolidation with bortezomib, thalidomide and dexamethasone in MM patients in CR or VGPR following autologous transplantation induces molecular remissions. Haematologica, 93, 76.
125. Palumbo, A., Rajkumar, S.V., Dimopoulos, M.A., Richardson, P.G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J.A., Cavo, M., Zangari, M., Attal, M., Belch, A., Knop, S., Joshua, D., Ludwig, H., Vesole, D., Blade, J., Kyle, R., Westin, J., Weber, D., Bringhen, S., Niesvizky, R., Waage, A., von Lilienfeld-Toal, M., Lonial, S., Morgan, G.J., Orlowski, R.Z., Shimizu, K., Anderson, K.C., Boccadoro, M., Durie, B.G., Sonneveld, P., Hussein, M.A. Sezer, O. (2008f) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 22, 414 423.
126. Panageas, K.S., Ben-Porat, L., Dickler, M.N., Chapman, P.B. Schrag, D. (2007) When you look matters: the effect of assessment schedule on progression-free survival. Journal of the National Cancer Institute, 99, 428 432. (Pubitemid 47073565)
127. Paripati, H., Stewart, A., Cabou, S., Dueck, A., Zepeda, V. Pirooz, N. (2008) Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia, 22, 1282 1284.
128. Pineda-Roman, M., Zangari, M., Haessler, J., Anaissie, E., Tricot, G., van, R.F., Crowley, J., Shaughnessy, Jr., J.D. Barlogie, B. (2008) Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. British Journal of Haematology, 140, 625 634.
129. Popat, R., Goff, L., Oakervee, H.E., Cavenagh, J.D. Joel, S.P. (2005) Changes in Mcl-1 and Bim expression with bortezomib and melphalan therapy for multiple myeloma. Blood, 106, 697a.
130. Popat, R., Oakervee, H.E., Hallam, S., Curry, N., Odeh, L., Foot, N., Esseltine, D.L., Drake, M., Morris, C. Cavenagh, J.D. (2008) Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. British Journal of Haematology, 141, 512 516.
131. Postorino, M., Pupo, L., Di Caprio, L., Campagna, S., Franceschini, L. Renzi, D. (2008) Sequential therapy with VAD, bortezomib and cyclophospamide as induction therapy for multiple myeloma: a sequential pharmacologic combination to achieve complete remissions before stem cell transplantation. Haematologica, 93, 89.
132. Rajkumar, S.V., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Kyle, R.A., Gertz, M.A. Greipp, P.R. (2000) Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clinic Proceedings, 75, 897 901.
133. Rajkumar, S.V., Hayman, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Greipp, P.R., Geyer, S., Iturria, N., Fonseca, R., Lust, J.A., Kyle, R.A. Witzig, T.E. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology, 20, 4319 4323. (Pubitemid 35266292)
134. Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., Zeldenrust, S.R., Kumar, S., Greipp, P.R., Fonseca, R., Lust, J.A., Russell, S.J., Kyle, R.A., Witzig, T.E. Gertz, M.A. (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106, 4050 4053. (Pubitemid 41775908)
135. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431 436. (Pubitemid 46630462)
136. Rajkumar, S.V., Jacobus, S., Callander, N., Fonseca, R., Vesole, D., Williams, M., Abonour, R., Siegel, D. Greipp, P. (2007) A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Blood, 110, 31a.
137. Rajkumar, S.V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J.B. Blade, J. (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology, 26, 2171 2177.
138. Reeder, C.B., Reece, D.E., Fonseca, R., Bergsagel, P.L., Hentz, J., Pirooz, N.A., Boesiger, J.E., Pisa, J.G., Kukreti, V., Chen, C., Trudel, S., Mikhael, J.R., Lacy, M., Rajkumar, S.V. Stewart, A.K. (2007) A phase II trial of myeloma induction therapy with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D): Improved response over historical lenalidomide-dexamethasone controls. Blood, 110, 1053a.
139. Reeder, C.B., Stewart, A.K., Hentz, J.G., Bergsagel, P.L., Pirooz, N.A., Fonseca, R., Chen, C., Trudel, S., Reece, D. Kukreti, V. (2008) Efficacy of induction with cybord in newly diagnosed multiple myeloma. Journal of Clinical Oncology, 26, Abstract 8517.
140. Richardson, P., Jagannath, S., Hussein, M., Berenson, J., Singhal, S., Irwin, D., Williams, S.F., Bensinger, W., Badros, A.Z., Vescio, R., Kenvin, L., Yu, Z., Olesnyckyj, M., Faleck, H., Zeldis, J., Knight, R. KC, A. (2005) A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood, 106, 449a.
141. Richardson, P.G., Briemberg, H., Jagannath, S., Wen, P.Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D.S., Irwin, D., Schuster, M., Srkalovic, G., Alexanian, R., Rajkumar, S.V., Limentani, S., Alsina, M., Orlowski, R.Z., Najarian, K., Esseltine, D., Anderson, K.C. Amato, A.A. (2006a) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology, 24, 3113 3120. (Pubitemid 46638949)
142. Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., Schlossman, R.L., Rajkumar, S.V., Desikan, K.R., Hideshima, T., Munshi, N.C., Kelly-Colson, K., Doss, D., McKenney, M.L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W.S., Zeldis, J., Knight, R., Weller, E. Anderson, K.C. (2006b) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, 3458 3464. (Pubitemid 44776887)
143. Richardson, P.G., Hideshima, T., Mitsiades, C. Anderson, K.C. (2007) The emerging role of novel therapies for the treatment of relapsed myeloma. Journal of the National Comprehensive Cancer Network, 5, 149 162. (Pubitemid 46423054)
144. Richardson, P.G., Niesvizky, R., Anderson, K.C. Bladé, J. (2008a) Re: when you look matters: the effect of assessment schedule on progression-free survival. Journal of the National Cancer Institute, 100, 373.
145. Richardson, P.G., Lonial, S., Jakubowiak, A., Jagannath, S., Raje, N.S., Avigan, D., Ghobrial, I.M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Vesole, D.H., Joyce, R., Doss, D., Warren, D.L., Hayes, S.W., Kaster, S., Delaney, C., Lauria, M., Mitsiades, C., Hideshima, T., Knight, R.D., Esseltine, D.-L. Anderson, K.C. (2008b) Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a Phase I/II study. Blood, 112, Abstract 92.
146. Rifkin, R.M., Gregory, S.A., Mohrbacher, A. Hussein, M.A. (2006) Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer, 106, 848 858. (Pubitemid 43238452)
147. Roodman, G.D. (2006) New potential targets for treating myeloma bone disease. Clinical Cancer Research, 12, 6270s 6273s. (Pubitemid 44703801)
148. Rosinol, L., Cibeira, M., Martinez, J., Mateos, M., Terol, M.J., De la Rubia, J., Palomera, L., de Arriba, F., Oriol, A., Alegre, A., Besalduch, J., de Paz, R., Garcia-Laraña, J., Díaz-Mediavilla, J., Sureda, A., Lahuerta, J.J., San Miguel, J.F. Blade, J. (2008) Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial. Blood, 112, Abstract 654.
149. Rosiñol, L., Oriol, A., Mateos, M., Sureda, A., Diaz-Mediavilla, J., Herrero, C., Liu, X., van de Velde, H., San Miguel, J. Bladé, J. (2007) Final results of a phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma (MM): efficacy and clinical implications of tumor response. Journal of Clinical Oncology, 25, 447s.
150. Roussel, M., Danho, C., Huynh, A. Attal, M. (2007) Velcade and high dose melphalan: a new preparative regimen. Haematologica, 92, 193.
151. Roussou, M., Kastritis, E., Migkou, M., Psimenou, E., Grapsa, I., Matsouka, C., Barmparousi, D., Terpos, E. Dimopoulos, M.A. (2008) Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leukaemia & Lymphoma, 49, 890 895.
152. San Miguel, J.F., Richardson, P., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W., Boral, A., Schenkein, D. Anderson, K. (2005) Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood, 106, 111a.
153. San Miguel, J.F., Schlag, R., Khuageva, N., Shpilberg, O., Dimopoulos, M., Kropff, M., Spicka, I., Petrucci, M., Samoilova, O., Dmoszynska, A., Abdulkadyrov, K., Schots, R., Jiang, B., Palumbo, A., Mateos, M., Liu, K., Cakana, A., van de Velde, H. Richardson, P. (2007) MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood, 110, 31a.
154. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.-V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906 917.
155. Sonneveld, P., van der Holt, B., Schmidt-Wolf, I., Bertsch, U., el Jarari, L., Salwender, H., Zweegman, S., Vellenga, E., Schubert, J., Blau, I.W., Jie, G.S.K., Beverloo, B., Jauch, A., Hose, D., Schaafsma, R., Kersten, M.J., Delforge, M., de Weerdt, O., van der Griend, R., Wijermans, P.W., Martin, H., van der Velde, H., Lokhorst, H.M. Goldschmidt, H. (2008) First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Blood, 112, Abstract 653.
156. Stewart, A.K., Bergsagel, P.L., Greipp, P.R., Dispenzieri, A., Gertz, M.A., Hayman, S.R., Kumar, S., Lacy, M.Q., Lust, J.A., Russell, S.J., Witzig, T.E., Zeldenrust, S.R., Dingli, D., Reeder, C.B., Roy, V., Kyle, R.A., Rajkumar, S.V. Fonseca, R. (2007) A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia, 21, 529 534. (Pubitemid 46306565)
157. Stewart, A.K., Reeder, B., Fonseca, R., Bergsagel, P.L., Pirooz, A. Hentz, G. (2008) Induction with CYBORD produces high complete responses in newly diagnosed multiple myeloma. Haematologica, 93, 82.
158. Terpos, E. Dimopoulos, M.A. (2005) Myeloma bone disease: pathophysiology and management. Annals of Oncology, 16, 1223 1231. (Pubitemid 41158467)
159. Terpos, E., Mihou, D., Szydlo, R., Tsimirika, K., Karkantaris, C., Politou, M., Voskaridou, E., Rahemtulla, A., Dimopoulos, M.A. Zervas, K. (2005) The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia, 19, 1969 1976. (Pubitemid 41554006)
160. Terpos, E., Delimpasi, S., Anargyrou, K., Baltathakis, I., Kastritis, E., Christoforidou, A., Tsionos, K., Tsatalas, K., Nikiforakis, E., Dimopoulos, M.A. Harhalakis, N. (2007) The combination of bortezomib, doxorubicin, and dexamethasone (PAD) is an effective regimen for high risk, newly diagnosed, patients with multiple myeloma, reduces bone resorption and normalizes angiopoietin-1 to angiopoietin-2 ratio. Blood, 110, 1051a.
161. Terpos, E., Christoulas, D., Kastritis, E., Katodritou, E. Kyrtsonis, M.-C. (2008a) Effect of lenalidomide-based regimens on bone remodeling in patients with relapsed/refractory multiple myeloma. Haematologica, 93, 76.
162. Terpos, E., Baltathakis, I., Anargyrou, K., Delimpasi, S., Kastritis, E. Christoforidou, A. (2008b) PAD regimen is effective in high risk, newly-diagnosed myeloma, reduces dickkopf-1 and abnormal bone resorption and normalizes impaired angiopoietin-1/-2 ratio. Haematologica, 93, 264.
163. Tosi, P., Zamagni, E., Cellini, C., Parente, R., Cangini, D. Tacchetti, P. (2006) First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. European Journal of Haematology, 76, 399 404.
164. van de Velde, H., Liu, X., Chen, G., Cakana, A., Deraedt, W. Bayssas, M. (2007) Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica, 92, 1399 1406. (Pubitemid 350144158)
165. Waage, A., Gimsing, P., Juliusson, G., Turesson, I. Fayers, P. (2007) Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. Blood, 110, Abstract 78.
166. Wang, M., Delasalle, K., Thomas, S., Giralt, S. Alexanian, R. (2006) Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood, 108, 123a 124a.
167. Wang, M., Giralt, S., Delasalle, K., Handy, B. Alexanian, R. (2007a) Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology, 12, 235 239. (Pubitemid 46930250)
168. Wang, M., Delasalle, K., Giralt, S. Alexanian, R. (2007b) Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide- dexamethasone (BLD). Blood, 110, 1057a.
169. Weber, D., Rankin, K., Gavino, M., Delasalle, K. Alexanian, R. (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology, 21, 16 19.
170. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133 2142. (Pubitemid 350146108)
171. White, D.J., Kovacs, M.J., Belch, A., Stewart, K., Chen, C., Rubin, S., Macdonald, D., Harnett, E., Chapman, J.-A.W., Shepherd, L.E. Meyer, R.M. (2007) Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: Toxicity data from the NCIC CTG MY.11 trial. Blood, 110, 63a.
172. Wijermans, P.W., Schaafsma, M.R., van Norden, Y., Ammerlaan, R., Sonneveld, P. Wittebol, S. (2008) MP vs MPT in induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVON. Haematologica, 93, 178.
173. Yoon, S.-S., Kim, H.J., Lee, D.S., Eom, H.S., Jang, J.H. Chung, J.S. (2008) Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (VELCADE®, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with VELCADE for newly diagnosed multiple myeloma: interim results of phase II trial. Haematologica, 93, 86.
174. Zangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A.V., Morris, C., Toor, A., Siegel, E., Fink, L. Tricot, G. (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood, 98, 1614 1615.
175. Zangari, M., Siegel, E., Barlogie, B., Anaissie, E., Saghafifar, F., Fassas, A., Morris, C., Fink, L. Tricot, G. (2002) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood, 100, 1168 1171.
176. Zangari, M., Elice, F., Fink, L. Tricot, G. (2007a) Thrombosis in multiple myeloma. Expert Review of Anticancer Therapy, 7, 307 315. (Pubitemid 46488336)
177. Zangari, M., Guerrero, J., Cavallo, F., Burns, M.J., Prasad, K., Adcock, D., Marlar, R., Tricot, G. Fink, L. (2007b) Coagulation-related effect of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Blood, 110, 803a.
178. Zangari, M., Cavallo, F., Suva, L., Dilley, J., Trico, G., Barlogie, B., Burns, M.J., Passera, R., Boccadoro, M., Esseltine, D. Yaccoby, S. (2007c) Prospective evaluation of the bone anabolic effect of bortezomib in relapsed multiple myeloma (MM) patients. Blood, 110, 798a.
179. Zervas, K., Dimopoulos, M.A., Hatzicharissi, E., Anagnostopoulos, A., Papaioannou, M., Mitsouli, C., Panagiotidis, P., Korantzis, J., Tzilianos, M. Maniatis, A. (2004) Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Annals of Oncology, 15, 134 138. (Pubitemid 38139615)
180. Zervas, K., Mihou, D., Katodritou, E., Pouli, A., Mitsouli, C. Anagnostopoulos, A. (2007) VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Annals of Oncology, 18, 1369 1375. (Pubitemid 47305012)
181. Zonder, J.A., Crowley, J., Hussein, M.A., Bolejack, V., Moore, D.F., Whittenberger, B.F., Adibi, M.H., Durie, B.G.M. Barlogie, B. (2007) Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): Results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. Blood, 110, 32a.